E. Pecher

Tegaserod, a 5‐HT₄ receptor partial agonist, relieves symptoms in irritable bowel syndrome patients with abdominal pain, bloating and constipation

S. Müller‐Lissner, I. Fumagalli, Karna Dev Bardhan et al. · Alimentary Pharmacology & Therapeutics · 2001 · 464 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +15

The effects of valsartan and captopril on reducing microalbuminuria in patients with type 2 diabetes mellitus: a placebo-controlled trial

Norman Muirhead, Brian F. Feagan, Jeffrey L. Mahon et al. · Current Therapeutic Research · 1999 · 87 citations

Medicine, Endocrinology, Pharmacotherapy +14

Long‐term safety of tegaserod in patients with constipation‐predominant irritable bowel syndrome

Gervais Tougas, W.J. Snape, M.H. Otten et al. · Alimentary Pharmacology & Therapeutics · 2002 · 77 citations

Medicine, Pharmacology, Pharmacotherapy +13

Comparison of nateglinide and gliclazide in combination with metformin, for treatment of patients with Type 2 diabetes mellitus inadequately controlled on maximum doses of metformin alone

Smiljana Ristič, C. Collober‐Maugeais, E. Pecher et al. · Diabetic Medicine · 2006 · 47 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +15

Nateglinide or gliclazide in combination with metformin for treatment of patients with type 2 diabetes mellitus inadequately controlled on maximum doses of metformin alone: 1‐year trial results

Smiljana Ristič, C. Collober‐Maugeais, Floriane Cressier et al. · Diabetes Obesity and Metabolism · 2006 · 32 citations

Medicine, Pharmacology, Pharmacotherapy +17